Accommodation amplitude change after cosmetic use of the botulinum toxin in the upper face
Cutaneous and Ocular Toxicology, cilt.44, sa.1, ss.135-139, 2025 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 44 Sayı: 1
- Basım Tarihi: 2025
- Doi Numarası: 10.1080/15569527.2025.2478416
- Dergi Adı: Cutaneous and Ocular Toxicology
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, EMBASE, Environment Index, MEDLINE
- Sayfa Sayıları: ss.135-139
- Anahtar Kelimeler: Abobotulinum toxin A, accommodation amplitude, adverse effect, botulinum toxin, cosmetic, upper face
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Purpose: Cosmetic botulinum toxin A (BoNT-A) injections are increasing worldwide. Adverse effects need to be evaluated in more detail for BoNT-A regulations. This study aims to assess the anticholinergic effect of BoNT-A on accommodation amplitude (AA) after upper face application. Methods: Twenty patients aged between 20 and 45 years were recruited in this prospective, interventional study. Abobotulinum toxin A of 500 units was diluted with 3 ml saline and injected into the forehead, glabellar and periorbital area. AA was measured with both the push-up and minus-lens techniques before and after two weeks of the injections. T-test for normally distributed variables was applied for the comparison of the results. Results: The study group comprised 18 women and 2 men with a mean age of 33.9 ± 8.59. AA decreased significantly after two weeks of the injection. In the push-up test, AA was 9.18 ± 4.72 D before BoNT-A injection and decreased to 7.11 ± 3.02 D after the injection (p < 0.001). In the minus lens test, AA reduced from 5.86 ± 2.24 D to 5.24 ± 2.06 D after BoNT-A injection (p < 0.001). Refraction did not change in any of the participants. Conclusion: The present study showed that cosmetic upper face BoNT-A injections reduced AA. However, this reduction did not result in any significant symptomatic effects in the patients. These findings suggest that while BoNT-A injection has a measurable impact on the ciliary muscle or its parasympathetic innervation, it may not lead to noticeable clinical outcomes.